These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial. Siika A; McCabe L; Bwakura-Dangarembizi M; Kityo C; Mallewa J; Berkley J; Maitland K; Griffiths A; Baleeta K; Mudzingwa S; Abach J; Nathoo K; Thomason MJ; Prendergast AJ; Walker AS; Gibb DM; Clin Infect Dis; 2018 Mar; 66(suppl_2):S140-S146. PubMed ID: 29514235 [TBL] [Abstract][Full Text] [Related]
7. Priorities for Decreasing Morbidity and Mortality in Children With Advanced HIV Disease. Frigati L; Archary M; Rabie H; Penazzato M; Ford N Clin Infect Dis; 2018 Mar; 66(suppl_2):S147-S151. PubMed ID: 29514237 [TBL] [Abstract][Full Text] [Related]
9. [Survival, clinical and biological outcomes of HIV-infected children treated by antiretroviral therapy in Africa: systematic review, 2004-2009]. Ndondoki C; Dabis F; Namale L; Becquet R; Ekouevi D; Bosse-Amani C; Arrivé E; Leroy V Presse Med; 2011; 40(7-8):e338-57. PubMed ID: 21295437 [TBL] [Abstract][Full Text] [Related]
10. Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review. Adejumo OA; Malee KM; Ryscavage P; Hunter SJ; Taiwo BO J Int AIDS Soc; 2015; 18(1):20049. PubMed ID: 26385853 [TBL] [Abstract][Full Text] [Related]
11. Retention and mortality on antiretroviral therapy in sub-Saharan Africa: collaborative analyses of HIV treatment programmes. Haas AD; Zaniewski E; Anderegg N; Ford N; Fox MP; Vinikoor M; Dabis F; Nash D; Sinayobye JD; Niyongabo T; Tanon A; Poda A; Adedimeji AA; Edmonds A; Davies MA; Egger M; J Int AIDS Soc; 2018 Feb; 21(2):. PubMed ID: 29479867 [TBL] [Abstract][Full Text] [Related]
12. The incidence rate of tuberculosis and its associated factors among HIV-positive persons in Sub-Saharan Africa: a systematic review and meta-analysis. Wondmeneh TG; Mekonnen AT BMC Infect Dis; 2023 Sep; 23(1):613. PubMed ID: 37723415 [TBL] [Abstract][Full Text] [Related]
13. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227 [TBL] [Abstract][Full Text] [Related]
14. Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis. Ravimohan S; Tamuhla N; Steenhoff AP; Letlhogile R; Makutu DK; Nfanyana K; Rantleru T; Tierney A; Nkakana K; Schwartz AB; Gross R; Macgregor RR; Bellamy SL; Frank I; Weissman D; Bisson GP J Infect Dis; 2013 Dec; 208(11):1784-93. PubMed ID: 23908475 [TBL] [Abstract][Full Text] [Related]
15. Pediatric Access and Continuity of HIV Care Before the Start of Antiretroviral Therapy in Sub-Saharan Africa. Bastard M; Poulet E; Nicolay N; Szumilin E; Balkan S; Pujades-Rodriguez M Pediatr Infect Dis J; 2016 Sep; 35(9):981-6. PubMed ID: 27187757 [TBL] [Abstract][Full Text] [Related]
16. Prevalence and factors associated with viral non-suppression in people living with HIV receiving antiretroviral therapy in sub-Saharan Africa: A systematic review and meta-analysis. Mosha IH; Nyondo GG; Munishi CG; Njiro BJ; Bwire GM Rev Med Virol; 2024 May; 34(3):e2540. PubMed ID: 38708846 [TBL] [Abstract][Full Text] [Related]
17. The Anti-inflammatory Effects of Cotrimoxazole Prophylaxis for People Living With Human Immunodeficiency Virus in Sub-Saharan Africa. Bourke CD; Prendergast AJ J Infect Dis; 2020 Jul; 222(3):347-350. PubMed ID: 31714953 [No Abstract] [Full Text] [Related]
18. Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. Marcy O; Laureillard D; Madec Y; Chan S; Mayaud C; Borand L; Prak N; Kim C; Lak KK; Hak C; Dim B; Sok T; Delfraissy JF; Goldfeld AE; Blanc FX; Clin Infect Dis; 2014 Aug; 59(3):435-45. PubMed ID: 24759827 [TBL] [Abstract][Full Text] [Related]
19. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa. Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203 [TBL] [Abstract][Full Text] [Related]
20. Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study. Ravimohan S; Tamuhla N; Steenhoff AP; Letlhogile R; Nfanyana K; Bellamy SL; MacGregor RR; Gross R; Weissman D; Bisson GP Lancet Infect Dis; 2015 Apr; 15(4):429-38. PubMed ID: 25672566 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]